Figure 1 (Noxafil 01)
Noxafil Solution
Product Images NDC 0085-4331
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 44 technical images submitted to the FDA as part of the official labeling for Noxafil (NDC 0085-4331). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Merck Sharp & Dohme Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Chemical Structure (Noxafil 02)
Figure A (Noxafil 02a)
Principal Display Panel (105 mL Bottle Carton)
NOXAFIL is an oral suspension medication that comes in a package of 105 mL. Each 5 mL contains 200mg of posaconazole. The medication comes with a measuring spoon for an accurate dosage. It is essential to note that NOXAFIL oral suspension and delayed-release tablets cannot be interchanged due to the difference in dosing. It is recommended to store the medication at 77°F and to shake the medication before consuming it.*
Principal Display Panel (60 Tablet Bottle Label)
Noxafl is a prescription medication that comes in a delayed-release tablet form containing 100mg of posaconazole. The medication is not interchangeable with Noxafl Oral Suspension due to differences in dosing. The tablets should be stored at room temperature between 68-77°F and 59-86°F. The product has a National Drug Code (NDC) of 0085-4324-02 and a GTIN of 00300854324025. The package contains 60 tablets.*
Principal Display Panel (16.7 mL Vial Carton)
Noxafil is an injectable medication containing 300mg posaconazole per 16.7 mL via, intended for intravenous use only. Inactive ingredients include 668 betadex suffobutyl ether sodium, 00033g edetate disodium, and hycochloric acid and sodium hydroxide to adjust the pH. The medication is manufactured for Merck Sharp & Dohme Corp, a subsidiary of Merck & Co, Inc. and manufactured by MSD International GmbH in Ireland. Noxafil is a clear, sterile solution that requires further dilution prior to infusion. The usual dosage information can be found in the accompanying directions, and any remaining solution should be stored in the refrigerator for up to 24 hours. The product is a sterile single-dose vial and requires a prescription.*
Figure (Noxafil 06)
Figure (Noxafil 07)
Figure (Noxafil 08)
Figure (Noxafil 09)
Figure (Noxafil 10)
Figure (Noxafil 11)
Figure (Noxafil 12)
Figure (Noxafil 13)
Figure (Noxafil 14)
Figure (Noxafil 15)
Figure (Noxafil 16)
Figure (Noxafil 17)
Figure (Noxafil 18)
Figure (Noxafil 19)
Figure (Noxafil 20)
Figure (Noxafil 21)
Figure (Noxafil 22)
Figure (Noxafil 23)
Figure (Noxafil 24)
Figure (Noxafil 25)
Figure (Noxafil 26)
Figure (Noxafil 27)
Figure (Noxafil 28)
Figure (Noxafil 29)
Figure (Noxafil 30)
Figure (Noxafil 31)
Figure (Noxafil 32)
Figure (Noxafil 33)
Figure (Noxafil 34)
Figure (Noxafil 35)
Figure (Noxafil 36)
Figure (Noxafil 37)
Figure (Noxafil 38)
Figure (Noxafil 39)
Figure (Noxafil 40)
Figure (Noxafil 41)
Figure (Noxafil 42)
Principal Display Panel (300 mg Carton)
Noxafil PowderMix is an oral suspension containing 300mg of posaconazole. It is stored at a room temperature of 20 to 25°C and should be administered with the provided notched-tip syringes within an hour of mixing. The recommended dosage and usage instructions can be found in the prescribing information provided. The Multi-Dose Kit contains instructions for use, syringes, mixing liquid, bottle adapter, and 8 packets of Noxafil PowderMix. Additional notched-tip syringes are provided in Package B.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
